Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
Clinical trial NCT03782792 · COMPLETED
Trial details
- NCT number
- NCT03782792
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-31
- Primary completion
- 2020-09-23
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.